Literature DB >> 16389585

The Val66Met polymorphism of the brain-derived neurotrophic factor gene is associated with risk for psychosis: evidence from a family-based association study.

Araceli Rosa1, Manuel J Cuesta, Mar Fatjó-Vilas, Víctor Peralta, Amalia Zarzuela, Lourdes Fañanás.   

Abstract

Schizophrenia (SZ) is a prevalent and severe mental disorder. One of the most favored hypotheses for the etiology of SZ is the neurodevelopmental hypothesis. Brain-derived neurotrophic factor (BDNF), a member of the neurotrophin growth factor family, promotes the development, regeneration, and survival of neurons and has been linked to the neuropathology of SZ. The present study tested, in a sample of 94 nuclear families, the hypothesis that the BDNF gene Val66Met polymorphism is associated to SZ and its psychopathologic phenotype using a multidimensional symptom approach. Furthermore, considering a reported reduction of BDNF in the frontal cortex of patients with SZ, we studied the relationship between this polymorphism and prefrontal function. The transmission disequilibrium test (TDT) showed a preferential transmission of allele Val from heterozygous parents to the affected offspring (P = 0.002), suggesting a possible role of this gene in the vulnerability to SZ spectrum disorders. The findings remained essentially unchanged when the analysis was restricted to the subgroup of patients with SZ (P = 0.009) and when a multidimensional approach to the diagnosis was used. Quantitative transmission disequilibrium test (QTDT) analyses did not demonstrate a significant association between the prefrontal tests assessed (Wisconsin Card Sorting Test and Trail Making Test) and the transmission of the BDNF alleles. Our finding suggests that the investigated BDNF polymorphism plays an important role in the phenotype of psychosis, but not in the performance of tests of prefrontal cognitive functions analyzed in these patients. (c) 2006 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16389585     DOI: 10.1002/ajmg.b.30266

Source DB:  PubMed          Journal:  Am J Med Genet B Neuropsychiatr Genet        ISSN: 1552-4841            Impact factor:   3.568


  18 in total

Review 1.  Pharmacogenetics of antidepressant response.

Authors:  Stefano Porcelli; Antonio Drago; Chiara Fabbri; Sara Gibiino; Raffaella Calati; Alessandro Serretti
Journal:  J Psychiatry Neurosci       Date:  2011-03       Impact factor: 6.186

2.  BDNF rs6265 methylation and genotype interact on risk for schizophrenia.

Authors:  Gianluca Ursini; Tommaso Cavalleri; Leonardo Fazio; Tiziana Angrisano; Luisa Iacovelli; Annamaria Porcelli; Giancarlo Maddalena; Giovanna Punzi; Marina Mancini; Barbara Gelao; Raffaella Romano; Rita Masellis; Francesca Calabrese; Antonio Rampino; Paolo Taurisano; Annabella Di Giorgio; Simona Keller; Letizia Tarantini; Lorenzo Sinibaldi; Tiziana Quarto; Teresa Popolizio; Grazia Caforio; Giuseppe Blasi; Marco A Riva; Antonio De Blasi; Lorenzo Chiariotti; Valentina Bollati; Alessandro Bertolino
Journal:  Epigenetics       Date:  2016-02-18       Impact factor: 4.528

Review 3.  The BDNF Val66Met Polymorphism Promotes Changes in the Neuronal Integrity and Alters the Time Perception.

Authors:  Victor Marinho; Giovanny Rebouças Pinto; Rogério Figueiredo; Carla Ayres; Juliete Bandeira; Silmar Teixeira
Journal:  J Mol Neurosci       Date:  2018-11-17       Impact factor: 3.444

4.  Interaction between catechol-O-methyltransferase (COMT) Val108/158Met and brain-derived neurotrophic factor (BDNF) Val66Met polymorphisms in age at onset and clinical symptoms in schizophrenia.

Authors:  S Numata; S Ueno; J Iga; K Yamauchi; S Hongwei; S Kinouchi; S Shibuya-Tayoshi; S Tayoshi; H Aki; S Sumitani; M Itakura; T Ohmori
Journal:  J Neural Transm (Vienna)       Date:  2006-08-08       Impact factor: 3.575

Review 5.  The BDNF gene Val66Met polymorphism as a modifier of psychiatric disorder susceptibility: progress and controversy.

Authors:  M Notaras; R Hill; M van den Buuse
Journal:  Mol Psychiatry       Date:  2015-03-31       Impact factor: 15.992

6.  No evidence for preferential transmission of common valine allele of the Val66Met polymorphism of the brain-derived neurotrophic factor gene (BDNF) in ADHD.

Authors:  B G Schimmelmann; S Friedel; A Dempfle; A Warnke; K P Lesch; S Walitza; T J Renner; M Romanos; B Herpertz-Dahlmann; M Linder; H Schäfer; C Seitz; H Palmason; C Freitag; J Meyer; K Konrad; A Hinney; J Hebebrand
Journal:  J Neural Transm (Vienna)       Date:  2007-01-15       Impact factor: 3.575

Review 7.  BDNF-TrkB signaling and neuroprotection in schizophrenia.

Authors:  Chirayu D Pandya; Ammar Kutiyanawalla; Anilkumar Pillai
Journal:  Asian J Psychiatr       Date:  2012-11-03

8.  Effect of the BDNF Val66Met polymorphism on regional gray matter volumes and cognitive function in the Chinese population.

Authors:  Mu-En Liu; Chu-Chung Huang; Mu-Hong Chen; Albert C Yang; Pei-Chi Tu; Heng-Liang Yeh; Chen-Jee Hong; Jin-Fan Chen; Jen-Ping Hwang; Ching-Po Lin; Shih-Jen Tsai
Journal:  Neuromolecular Med       Date:  2013-12-24       Impact factor: 3.843

Review 9.  Myelin, copper, and the cuprizone model of schizophrenia.

Authors:  Nicole R Herring; Christine Konradi
Journal:  Front Biosci (Schol Ed)       Date:  2011-01-01

10.  Population genetic study of the brain-derived neurotrophic factor (BDNF) gene.

Authors:  T L Petryshen; P C Sabeti; K A Aldinger; B Fry; J B Fan; S F Schaffner; S G Waggoner; A R Tahl; P Sklar
Journal:  Mol Psychiatry       Date:  2009-03-03       Impact factor: 15.992

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.